Media coverage about DURECT (NASDAQ:DRRX) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. DURECT earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave news coverage about the specialty pharmaceutical company an impact score of 47.3364437767867 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Several analysts recently commented on DRRX shares. Laidlaw lowered their target price on DURECT from $3.00 to $2.00 and set a “buy” rating on the stock in a research report on Friday, October 20th. ValuEngine cut DURECT from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 21st. Stifel Nicolaus cut DURECT from a “buy” rating to a “hold” rating in a research report on Friday, October 20th. Finally, HC Wainwright restated a “hold” rating on shares of DURECT in a research report on Thursday, November 2nd.
DURECT (NASDAQ DRRX) traded up $0.01 on Thursday, reaching $1.16. The company had a trading volume of 452,800 shares, compared to its average volume of 1,199,555. DURECT has a 12-month low of $0.74 and a 12-month high of $2.17. The company has a current ratio of 1.67, a quick ratio of 1.57 and a debt-to-equity ratio of 1.46. The firm has a market cap of $174.04, a PE ratio of -7.73 and a beta of 1.68.
Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.
Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.